Guest guest Posted June 27, 2002 Report Share Posted June 27, 2002 Hi -- I am doing well. Unfortunately my Mom is in the hospital due to pain caused by 6 ulcers in her esophagus. They were caused when one of the glass " beads " escaped from her liver. She's been in the hospital for a week today, but should go home in another day or two. Then a home health agency will help her monitor the pain. The doctors want to let her esophagus rest for a few weeks, so she will be fed through her portacath. Other than that, she is doing pretty well. This was the second Therasphere treatment (one per lobe in the liver). She had scans taken just before this treatment, which showed there was tumor shrinkage in the lobe that was treated first. She had virtually no side effects the first treatment, which was mid May. Her oncologist was concerned about Celebrex causing liver damage and therefore didn't recommend she take it. Have you (or anyone else) heard anything about that? Thanks, ! > > How are you and your Mom doing (well I hope!)? Did she try the > radioactive spheres? What was the experience like? > > Best Wishes, > > > > > > > > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted June 27, 2002 Report Share Posted June 27, 2002 Hi , I've been very interested in Therasphere for some time as a treatment for " advanced " liver disease - seems like maybe it could be of great benefit for such patients. I'd always kinda wondered how they " made sure " none of the theraspheres got loose and went somewhere they shouldn't though (still not sure!) Sorry to hear about your mom - hope that she will get out of the hospital soon! On the positive side, it sounds like the treatment worked! Glad you brought up the issue of Celebrex side effects...no drug is " risk free " , there are ALWAYS side effects for somebody....but overall I think Celebrex seems pretty mild as these things go. One excellent source of information about Celebrex is the " package insert " which may be found at http://www.celebrex.com/us_prescribing_info.asp (need adobe acrobat reader - free - to view) It looks like they are a little concerned about effects in patients with compromised liver and/or kidney function, so maybe that's why they didn't want to give to your mom. I have been taking it for a year now, I have regular liver and kidney function labs and nothing has ever been " off " Now the LOVASTATIN mentioned in the LEF article to be given with the Celebrex is a different story. Statins in general are hard on the liver, and my oncologist didn't want me to take them for a few months after liver resection. I started taking Red Yeast Rice instead (just took dose recommended on the bottle) A quick summary of important points about Celebrex from the Package Insert: 1) TAKE IT WITH FOOD - ESPECIALLY IMPORTANT FOR THE HIGH DOSE REQUIRED FOR FAP AND EXPERIMENTALLY FOR COLON CANCER TREATMENT When CELEBREX capsules were taken with a high fat meal, peak plasma levels were delayed for about 1 to 2 hours with an increase in total absorption (AUC) of 10% to 20%. Under fasting conditions, at doses above 200 mg, there is less than a proportional increase in Cmax and AUC, which is thought to be due to the low solubility of the drug in aqueous media. 2) DON'T TAKE IT WITH ANTACIDS - DOESN'T ABSORB AS WELL Coadministration of CELEBREX with an aluminum- and magnesium- containing antacid resulted in a reduction in plasma celecoxib concentrations with a decrease of 37% in Cmax and 10% in AUC. CELEBREX, at doses up to 200 mg BID can be administered without regard to timing of meals. Higher doses (400 mg BID) should be administered with food to improve absorption. 3) NOT RECOMMENDED FOR PATIENTS WITH SEVERE LIVER IMPAIRMENT Hepatic Insufficiency: A pharmacokinetic study in subjects with mild (Child-Pugh Class I) and moderate (Child-Pugh Class II) hepatic impairment has shown that steady-state celecoxib AUC is increased about 40% and 180%, respectively, above that seen in healthy control subjects. Therefore, the daily recommended dose of CELEBREX capsules should be reduced by approximately 50% in patients with moderate (Child-Pugh Class II) hepatic impairment. Patients with severe hepatic impairment have not been studied. The use of CELEBREX in patients with severe hepatic impairment is not recommended. Hepatic Effects: Borderline elevations of one or more liver associated enzymes may occur in up to 15% of patients taking NSAIDs, and notable elevations of ALT or AST (approximately 3 or more times the upper limit of normal) have been reported in approximately 1% of patients in clinical trials with NSAIDs. These laboratory abnormalities may progress, may remain unchanged, or may be transient with continuing therapy. Rare cases of severe hepatic reactions, including jaundice and fatal fulminant hepatitis, liver necrosis and hepatic failure (some with fatal outcome) have been reported with NSAIDs, including CELEBREX (see ADVERSE REACTIONS — post-marketing experience). In controlled clinical trials of CELEBREX, the incidence of borderline elevations (greater than or equal to 1.2 times and less than 3 times the upper limit of normal) of liver associated enzymes was 6% for CELEBREX and 5% for placebo, and approximately 0.2% of patients taking CELEBREX and 0.3% of patients taking placebo had notable elevations of ALT and AST. A patient with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver test has occurred, should be monitored carefully for evidence of the development of a more severe hepatic reaction while on therapy with CELEBREX. If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.), CELEBREX should be discontinued. 4) NOT RECOMMENDED FOR PATIENTS WITH KIDNEY DISFUNCTION Renal Insufficiency: In a cross-study comparison, celecoxib AUC was approximately 40% lower in patients with chronic renal insufficiency (GFR 35–60 mL/min) than that seen in subjects with normal renal function. No significant relationship was found between GFR and celecoxib clearance. Patients with severe renal insufficiency have not been studied. Similar to other NSAIDs, CELEBREX is not recommended in patients with severe renal insufficiency (see WARNINGS — Advanced Renal Disease). Advanced Renal Disease No information is available from controlled clinical studies regarding the use of CELEBREX in patients with advanced kidney disease. Therefore, treatment with CELEBREX is not recommended in these patients with advanced kidney disease. If CELEBREX therapy must be initiated, close monitoring of the patient's kidney function is advisable (see PRECAUTIONS — Renal Effects). Renal Effects: Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of a nonsteroidal anti-inflammatory drug may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state. Clinical trials with CELEBREX have shown renal effects similar to those observed with comparator NSAIDs. Caution should be used when initiating treatment with CELEBREX in patients with considerable dehydration. It is advisable to rehydrate patients first and then start therapy with CELEBREX. Caution is also recommended in patients with preexisting kidney disease (see WARNINGS — Advanced Renal Disease). 5) CELEBREX HAS BEEN PROVEN TO REDUCE THE NUMBER OF POLYPS IN PATINETS WITH FAP AND THE GREATEST PERCENT REDUCTION OCCURRED AT THE HIGHEST DOSE (400 MG TWICE A DAY). FAP IS NOT THE SAME AS METASTATIC COLON CANCER, HOWEVER RECENT TRIALS REPORTED AT ASCO INDICATED METASTATIC CC PATIENTS TAKING CELEBREX WITH XELODA HAD AN IMPROVED TIME TO PROGRESSION. Familial Adenomatous Polyposis (FAP): CELEBREX was evaluated to reduce the number of adenomatous colorectal polyps. A randomized double-blind placebo-controlled study was conducted in 83 patients with FAP. The study population included 58 patients with a prior subtotal or total colectomy and 25 patients with an intact colon. Thirteen patients had the attenuated FAP phenotype. One area in the rectum and up to four areas in the colon were identified at baseline for specific follow-up, and polyps were counted at baseline and following six months of treatment. The mean reduction in the number of colorectal polyps was 28% for CELEBREX 400 mg BID, 12% for CELEBREX 100 mg BID and 5% for placebo. The reduction in polyps observed with CELEBREX 400 mg BID was statistically superior to placebo at the six-month timepoint (p = 0.003). (See Figure 1.) 6) DID NOT APPEAR TO AFFECT BLOOD CLOTTING Platelets: In clinical trials, CELEBREX at single doses up to 800 mg and multiple doses of 600 mg BID for up to 7 days duration (higher than recommended therapeutic doses) had no effect on platelet aggregation and bleeding time. Comparators (naproxen 500 mg BID, ibuprofen 800 mg TID, diclofenac 75 mg BID) significantly reduced platelet aggregation and prolonged bleeding time. 7) CONTRAINDICATIONS - BE CAREFUL IF YOU ARE ALLERGIC TO SULFONAMIDES CELEBREX is contraindicated in patients with known hypersensitivity to celecoxib. CELEBREX should not be given to patients who have demonstrated allergic-type reactions to sulfonamides. CELEBREX should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients (see WARNINGS — Anaphylactoid Reactions, and PRECAUTIONS — Preexisting Asthma). 8) MAY REDUCE EFFECTS OF ACE INHIBITORS ACE-inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors. This interaction should be given consideration in patients taking CELEBREX concomitantly with ACEinhibitors. 9) MAY INCREASE RISK OF GI BLEEDING - SHOULD BE USED WITH CAUTION IN PATIENTS WITH PRIOR HISTORY OF ULCERS OR GI BLEEDS - BUT THE ACTUAL PERCENT OF PATIENTS EXPERIENCING THIS IS STILL SMALL In a small number of patients with a history of ulcer disease, the complicated and symptomatic ulcer rates in patients taking CELEBREX alone or CELEBREX with ASA were, respectively, 2.56% (n=243) and 6.85% (n=91) at 48 weeks. These results are to be expected in patients with a prior history of ulcer disease (see WARNINGS — Gastrointestinal (GI) Effects — Risk of GI Ulceration, Bleeding, and Perforation). NSAIDs should be prescribed with extreme caution in patients with a prior history of ulcer disease or gastrointestinal bleeding. Most spontaneous reports of fatal GI events are in elderly or debilitated patients and therefore special care should be taken in treating this population. To minimize the potential risk for an adverse GI event, the lowest effective dose should be used for the shortest possible duration. For high risk patients, alternate therapies that do not involve NSAIDs should be considered. Studies have shown that patients with a prior history of peptic ulcer disease and/or gastrointestinal bleeding and who use NSAIDs, have a greater than 10-fold higher risk for developing a GI bleed than patients with neither of these risk factors. In addition to a past history of ulcer disease, pharmacoepidemiological studies have identified several other cotherapies or co-morbid conditions that may increase the risk for GI bleeding such as: treatment with oral corticosteroids, treatment with anticoagulants, longer duration of NSAID therapy, smoking, alcoholism, older age, and poor general health status. 10) OVERALL, BAD SIDE EFFECTS APPEARED RARE AND EVEN HIGH DOSES SUCH AS 400 MG BID ARE WELL TOLERATED Adverse events from the controlled trial in familial adenomatous polyposis: The adverse event profile reported for the 83 patients with familial adenomatous polyposis enrolled in the randomized, controlled clinical trial was similar to that reported for patients in the arthritis controlled trials. Intestinal anastomotic ulceration was the only new adverse event reported in the FAP trial, regardless of causality, and was observed in 3 of 58 patients (one at 100 mg BID, and two at 400 mg BID) who had prior intestinal surgery. No overdoses of CELEBREX were reported during clinical trials. Doses up to 2400 mg/day for up to 10 days in 12 patients did not result in serious toxicity. Symptoms following acute NSAID overdoses are usually limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which are generally reversible with supportive care. Gastrointestinal bleeding can occur. Hypertension, acute renal failure, respiratory depression and coma may occur, but are rare. Anaphylactoid reactions have been reported with therapeutic ingestion of NSAIDs, and may occur following an overdose. > Hi -- > > I am doing well. Unfortunately my Mom is in the hospital due to pain caused > by 6 ulcers in her esophagus. They were caused when one of the glass > " beads " escaped from her liver. She's been in the hospital for a week > today, but should go home in another day or two. Then a home health agency > will help her monitor the pain. The doctors want to let her esophagus rest > for a few weeks, so she will be fed through her portacath. Other than that, > she is doing pretty well. This was the second Therasphere treatment (one > per lobe in the liver). She had scans taken just before this treatment, > which showed there was tumor shrinkage in the lobe that was treated first. > She had virtually no side effects the first treatment, which was mid May. > > Her oncologist was concerned about Celebrex causing liver damage and > therefore didn't recommend she take it. Have you (or anyone else) heard > anything about that? > > Thanks, > > > > > ! > > > > > > How are you and your Mom doing (well I hope!)? Did she try the > > radioactive spheres? What was the experience like? > > > > Best Wishes, > > > > > > > > > > > > > > > > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted June 27, 2002 Report Share Posted June 27, 2002 Hi , I've been very interested in Therasphere for some time as a treatment for " advanced " liver disease - seems like maybe it could be of great benefit for such patients. I'd always kinda wondered how they " made sure " none of the theraspheres got loose and went somewhere they shouldn't though (still not sure!) Sorry to hear about your mom - hope that she will get out of the hospital soon! On the positive side, it sounds like the treatment worked! Glad you brought up the issue of Celebrex side effects...no drug is " risk free " , there are ALWAYS side effects for somebody....but overall I think Celebrex seems pretty mild as these things go. One excellent source of information about Celebrex is the " package insert " which may be found at http://www.celebrex.com/us_prescribing_info.asp (need adobe acrobat reader - free - to view) It looks like they are a little concerned about effects in patients with compromised liver and/or kidney function, so maybe that's why they didn't want to give to your mom. I have been taking it for a year now, I have regular liver and kidney function labs and nothing has ever been " off " Now the LOVASTATIN mentioned in the LEF article to be given with the Celebrex is a different story. Statins in general are hard on the liver, and my oncologist didn't want me to take them for a few months after liver resection. I started taking Red Yeast Rice instead (just took dose recommended on the bottle) A quick summary of important points about Celebrex from the Package Insert: 1) TAKE IT WITH FOOD - ESPECIALLY IMPORTANT FOR THE HIGH DOSE REQUIRED FOR FAP AND EXPERIMENTALLY FOR COLON CANCER TREATMENT When CELEBREX capsules were taken with a high fat meal, peak plasma levels were delayed for about 1 to 2 hours with an increase in total absorption (AUC) of 10% to 20%. Under fasting conditions, at doses above 200 mg, there is less than a proportional increase in Cmax and AUC, which is thought to be due to the low solubility of the drug in aqueous media. 2) DON'T TAKE IT WITH ANTACIDS - DOESN'T ABSORB AS WELL Coadministration of CELEBREX with an aluminum- and magnesium- containing antacid resulted in a reduction in plasma celecoxib concentrations with a decrease of 37% in Cmax and 10% in AUC. CELEBREX, at doses up to 200 mg BID can be administered without regard to timing of meals. Higher doses (400 mg BID) should be administered with food to improve absorption. 3) NOT RECOMMENDED FOR PATIENTS WITH SEVERE LIVER IMPAIRMENT Hepatic Insufficiency: A pharmacokinetic study in subjects with mild (Child-Pugh Class I) and moderate (Child-Pugh Class II) hepatic impairment has shown that steady-state celecoxib AUC is increased about 40% and 180%, respectively, above that seen in healthy control subjects. Therefore, the daily recommended dose of CELEBREX capsules should be reduced by approximately 50% in patients with moderate (Child-Pugh Class II) hepatic impairment. Patients with severe hepatic impairment have not been studied. The use of CELEBREX in patients with severe hepatic impairment is not recommended. Hepatic Effects: Borderline elevations of one or more liver associated enzymes may occur in up to 15% of patients taking NSAIDs, and notable elevations of ALT or AST (approximately 3 or more times the upper limit of normal) have been reported in approximately 1% of patients in clinical trials with NSAIDs. These laboratory abnormalities may progress, may remain unchanged, or may be transient with continuing therapy. Rare cases of severe hepatic reactions, including jaundice and fatal fulminant hepatitis, liver necrosis and hepatic failure (some with fatal outcome) have been reported with NSAIDs, including CELEBREX (see ADVERSE REACTIONS — post-marketing experience). In controlled clinical trials of CELEBREX, the incidence of borderline elevations (greater than or equal to 1.2 times and less than 3 times the upper limit of normal) of liver associated enzymes was 6% for CELEBREX and 5% for placebo, and approximately 0.2% of patients taking CELEBREX and 0.3% of patients taking placebo had notable elevations of ALT and AST. A patient with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver test has occurred, should be monitored carefully for evidence of the development of a more severe hepatic reaction while on therapy with CELEBREX. If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.), CELEBREX should be discontinued. 4) NOT RECOMMENDED FOR PATIENTS WITH KIDNEY DISFUNCTION Renal Insufficiency: In a cross-study comparison, celecoxib AUC was approximately 40% lower in patients with chronic renal insufficiency (GFR 35–60 mL/min) than that seen in subjects with normal renal function. No significant relationship was found between GFR and celecoxib clearance. Patients with severe renal insufficiency have not been studied. Similar to other NSAIDs, CELEBREX is not recommended in patients with severe renal insufficiency (see WARNINGS — Advanced Renal Disease). Advanced Renal Disease No information is available from controlled clinical studies regarding the use of CELEBREX in patients with advanced kidney disease. Therefore, treatment with CELEBREX is not recommended in these patients with advanced kidney disease. If CELEBREX therapy must be initiated, close monitoring of the patient's kidney function is advisable (see PRECAUTIONS — Renal Effects). Renal Effects: Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of a nonsteroidal anti-inflammatory drug may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state. Clinical trials with CELEBREX have shown renal effects similar to those observed with comparator NSAIDs. Caution should be used when initiating treatment with CELEBREX in patients with considerable dehydration. It is advisable to rehydrate patients first and then start therapy with CELEBREX. Caution is also recommended in patients with preexisting kidney disease (see WARNINGS — Advanced Renal Disease). 5) CELEBREX HAS BEEN PROVEN TO REDUCE THE NUMBER OF POLYPS IN PATINETS WITH FAP AND THE GREATEST PERCENT REDUCTION OCCURRED AT THE HIGHEST DOSE (400 MG TWICE A DAY). FAP IS NOT THE SAME AS METASTATIC COLON CANCER, HOWEVER RECENT TRIALS REPORTED AT ASCO INDICATED METASTATIC CC PATIENTS TAKING CELEBREX WITH XELODA HAD AN IMPROVED TIME TO PROGRESSION. Familial Adenomatous Polyposis (FAP): CELEBREX was evaluated to reduce the number of adenomatous colorectal polyps. A randomized double-blind placebo-controlled study was conducted in 83 patients with FAP. The study population included 58 patients with a prior subtotal or total colectomy and 25 patients with an intact colon. Thirteen patients had the attenuated FAP phenotype. One area in the rectum and up to four areas in the colon were identified at baseline for specific follow-up, and polyps were counted at baseline and following six months of treatment. The mean reduction in the number of colorectal polyps was 28% for CELEBREX 400 mg BID, 12% for CELEBREX 100 mg BID and 5% for placebo. The reduction in polyps observed with CELEBREX 400 mg BID was statistically superior to placebo at the six-month timepoint (p = 0.003). (See Figure 1.) 6) DID NOT APPEAR TO AFFECT BLOOD CLOTTING Platelets: In clinical trials, CELEBREX at single doses up to 800 mg and multiple doses of 600 mg BID for up to 7 days duration (higher than recommended therapeutic doses) had no effect on platelet aggregation and bleeding time. Comparators (naproxen 500 mg BID, ibuprofen 800 mg TID, diclofenac 75 mg BID) significantly reduced platelet aggregation and prolonged bleeding time. 7) CONTRAINDICATIONS - BE CAREFUL IF YOU ARE ALLERGIC TO SULFONAMIDES CELEBREX is contraindicated in patients with known hypersensitivity to celecoxib. CELEBREX should not be given to patients who have demonstrated allergic-type reactions to sulfonamides. CELEBREX should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients (see WARNINGS — Anaphylactoid Reactions, and PRECAUTIONS — Preexisting Asthma). 8) MAY REDUCE EFFECTS OF ACE INHIBITORS ACE-inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors. This interaction should be given consideration in patients taking CELEBREX concomitantly with ACEinhibitors. 9) MAY INCREASE RISK OF GI BLEEDING - SHOULD BE USED WITH CAUTION IN PATIENTS WITH PRIOR HISTORY OF ULCERS OR GI BLEEDS - BUT THE ACTUAL PERCENT OF PATIENTS EXPERIENCING THIS IS STILL SMALL In a small number of patients with a history of ulcer disease, the complicated and symptomatic ulcer rates in patients taking CELEBREX alone or CELEBREX with ASA were, respectively, 2.56% (n=243) and 6.85% (n=91) at 48 weeks. These results are to be expected in patients with a prior history of ulcer disease (see WARNINGS — Gastrointestinal (GI) Effects — Risk of GI Ulceration, Bleeding, and Perforation). NSAIDs should be prescribed with extreme caution in patients with a prior history of ulcer disease or gastrointestinal bleeding. Most spontaneous reports of fatal GI events are in elderly or debilitated patients and therefore special care should be taken in treating this population. To minimize the potential risk for an adverse GI event, the lowest effective dose should be used for the shortest possible duration. For high risk patients, alternate therapies that do not involve NSAIDs should be considered. Studies have shown that patients with a prior history of peptic ulcer disease and/or gastrointestinal bleeding and who use NSAIDs, have a greater than 10-fold higher risk for developing a GI bleed than patients with neither of these risk factors. In addition to a past history of ulcer disease, pharmacoepidemiological studies have identified several other cotherapies or co-morbid conditions that may increase the risk for GI bleeding such as: treatment with oral corticosteroids, treatment with anticoagulants, longer duration of NSAID therapy, smoking, alcoholism, older age, and poor general health status. 10) OVERALL, BAD SIDE EFFECTS APPEARED RARE AND EVEN HIGH DOSES SUCH AS 400 MG BID ARE WELL TOLERATED Adverse events from the controlled trial in familial adenomatous polyposis: The adverse event profile reported for the 83 patients with familial adenomatous polyposis enrolled in the randomized, controlled clinical trial was similar to that reported for patients in the arthritis controlled trials. Intestinal anastomotic ulceration was the only new adverse event reported in the FAP trial, regardless of causality, and was observed in 3 of 58 patients (one at 100 mg BID, and two at 400 mg BID) who had prior intestinal surgery. No overdoses of CELEBREX were reported during clinical trials. Doses up to 2400 mg/day for up to 10 days in 12 patients did not result in serious toxicity. Symptoms following acute NSAID overdoses are usually limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which are generally reversible with supportive care. Gastrointestinal bleeding can occur. Hypertension, acute renal failure, respiratory depression and coma may occur, but are rare. Anaphylactoid reactions have been reported with therapeutic ingestion of NSAIDs, and may occur following an overdose. > Hi -- > > I am doing well. Unfortunately my Mom is in the hospital due to pain caused > by 6 ulcers in her esophagus. They were caused when one of the glass > " beads " escaped from her liver. She's been in the hospital for a week > today, but should go home in another day or two. Then a home health agency > will help her monitor the pain. The doctors want to let her esophagus rest > for a few weeks, so she will be fed through her portacath. Other than that, > she is doing pretty well. This was the second Therasphere treatment (one > per lobe in the liver). She had scans taken just before this treatment, > which showed there was tumor shrinkage in the lobe that was treated first. > She had virtually no side effects the first treatment, which was mid May. > > Her oncologist was concerned about Celebrex causing liver damage and > therefore didn't recommend she take it. Have you (or anyone else) heard > anything about that? > > Thanks, > > > > > ! > > > > > > How are you and your Mom doing (well I hope!)? Did she try the > > radioactive spheres? What was the experience like? > > > > Best Wishes, > > > > > > > > > > > > > > > > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted March 22, 2004 Report Share Posted March 22, 2004 We missed you and Kennedy! I will give you a call at the delta chelsea if your still there on tuesday. I hope KK likes her butterfly picture KK is in my thoughts! Chantelle Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.